Loading...
ATRI logo

Atrion CorporationNasdaqGS:ATRI Stok Raporu

Piyasa Değeri US$809.4m
Hisse Fiyatı
n/a
1Y-3.1%
7D0.1%
1D0%
Portföy Değeri
​
Görünüm

Atrion Corporation

NasdaqGS:ATRI Stok Raporu

Piyasa değeri: US$809.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Atrion (ATRI) Hisse Özeti

Develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. Daha fazla detay

Risk Analizi

Kazançlar son 5 yılda yılda 11.4% oranında azaldı

Kar marjları (6.9%) geçen yılın (15.9%) altında

1.91% temettüsü kazançlar tarafından iyi karşılanmıyor


ATRI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW436,082 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
436,082 investors already sharing narratives
View all narratives

Atrion Corporation Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Atrion
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıUS$459.92
52 Haftanın En Yüksek SeviyesiUS$503.24
52 Haftanın En Düşük SeviyesiUS$274.98
Beta0.69
1 Aylık Değişim0.62%
3 Aylık Değişim-0.88%
1 Yıllık Değişim-3.11%
3 Yıllık Değişim-35.22%
5 Yıllık Değişim-40.14%
Halka arzdan bu yana değişim1,790.08%

Son Haberler & Güncellemeler

Recent updates

Analiz Makalesi • May 22

There May Be Some Bright Spots In Atrion's (NASDAQ:ATRI) Earnings

Soft earnings didn't appear to concern Atrion Corporation's ( NASDAQ:ATRI ) shareholders over the last week. We did...
Seeking Alpha • Mar 24

Atrion Corporation Is Overvalued For The Direction Fundamentals Are Heading

Summary Atrion Corporation, a healthcare company focused on fluid delivery products, has experienced a decline in revenue, profits, and cash flows. The drop in sales of fluid delivery products, which account for 42% of overall revenue, has severely impacted the company's top line. Despite the potential for improvement in the future, the stock is currently expensive compared to similar companies, warranting a cautious outlook and a downgrade to a 'sell' rating. Read the full article on Seeking Alpha
Analiz Makalesi • Mar 23

Subdued Growth No Barrier To Atrion Corporation (NASDAQ:ATRI) With Shares Advancing 25%

Atrion Corporation ( NASDAQ:ATRI ) shareholders would be excited to see that the share price has had a great month...
Analiz Makalesi • Feb 09

Here's Why Atrion (NASDAQ:ATRI) Can Manage Its Debt Responsibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analiz Makalesi • Jan 04

Atrion Corporation's (NASDAQ:ATRI) 26% Share Price Surge Not Quite Adding Up

Those holding Atrion Corporation ( NASDAQ:ATRI ) shares would be relieved that the share price has rebounded 26% in the...
Analiz Makalesi • Sep 14

Atrion (NASDAQ:ATRI) Seems To Use Debt Quite Sensibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analiz Makalesi • Jul 18

Atrion (NASDAQ:ATRI) Will Want To Turn Around Its Return Trends

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
Analiz Makalesi • Apr 19

Be Wary Of Atrion (NASDAQ:ATRI) And Its Returns On Capital

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Analiz Makalesi • Oct 18

Atrion (NASDAQ:ATRI) May Have Issues Allocating Its Capital

There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...
Seeking Alpha • Sep 08

Atrion: Attractively Priced For Exposure To Defensive Healthcare

Summary Artrion Corp. looks well positioned to continue delivering stable, predictable future cash flows. The stock is ideal for those seeking defensive characteristics into equity portfolios. Shares look attractively priced by our estimate of fair value. We rate ATRI a buy on a $632 valuation. Investment Summary Defensive healthcare looks well positioned to catch a bid in the current investment landscape as investors turn to factors of quality and resiliency. Earnings quality and fundamental momentum are paramount to overcome the deep drawdowns experienced across equity markets in FY22. With that, we look to Atrion Corporation (ATRI), a low volatility offering with extensive business history and deep customer networks. ATRI is ideal for investors seeking to add a defensive overlay to equity portfolios, and shares look attractively priced by our estimation. There's also the $2.15 recently declared dividend [+10.3% YoY] that is not discussed here. We rate ATRI a buy $632 price target. Atrion Q2 earnings: in-line with mature growth cycle ATRI came in with a strong set of numbers once again, with top-line growth of 14% printing quarterly revenue of $48.9 million ("mm"). The bolus of upside was driven by a 37% YoY gain in cardiovascular revenues, and 'other' revenues of 14%, offset by weakness in fluid delivery and ophthalmology, as seen in Exhibit 1. Meanwhile, COGS saw a 13% YoY gain due to the higher revenue volumes, whereas inventories lifted by ~690bps YoY. The spike in inventory value was driven by a 13% increase in raw material value, in-line with market trends and the commodity bull run of the past 12 months. This resulted in a gross profit of $20.8mm, up 16.6% YoY on a gross margin of 42.6%. Exhibit 1. The cardiovascular business continues to be the major performer on a sequential basis. Revenue split continues to shift toward a more even distribution towards cardiovascular. Cardiovascular margin is now ~37% of turnover in Q2 FY22. Note: Adapted from ATRI Q2 FY22 10-Q (Image: HB Insights. Data: ATRI) As seen in Exhibit 2, quarterly operating trends have been consistently buoyant for ATRI from FY15-date. Both turnover and operating profit have ticked up from low-points during the pandemic, whereas FCF [net of dividends] has been narrowing from FY20-date. We note the QoQ decline in FCF yield that investors have realized over this time, which, at face value looks to be quite alarming. Exhibit 2. Quarterly operating metrics demonstrate the resiliency on offer, with sales and pre-tax earnings both lifting back above pre-pandemic levels. Noted is the declining FCF yield on tighter FCF conversion, however, as we discuss below, this is coupled with favorable return on investment to justify the case. Note: [All earnings figures in $mm or %]. Quarterly operating measures are plotted against TTM FCF yield to observe effect of invested capital and return on invested capital. Calculations are made from GAAP earnings with no reconciliations. (Image: HB Insights; Data: ATRI SEC Filings) In light of the tightening FCF and FCF yields our findings illustrate that ATRI's return on investment has remained in the double digits across the examination period. Whilst FCF [net of dividends] has narrowed sequentially, ROIC has remained high and curled up since late FY21 on a TTM basis, as seen in Exhibit 3. This tells us the company is amid a strong capital budgeting cycle that has seen it invest more than it made during the period [in Q2 FY22 in particular]. The combination of negative FCF and rising return on investment is a favorable combination that is incredibly attractive in the current climate. Exhibit 3. Despite tightening FCF and realized FCF yields since FY15, ATRI continuously delivers double-digit return on investment that comfortably outpaces the WACC hurdle of 5% by ~2.8 turns. Note: All figures are in $mm or %. Invested capital is calculated with capitalized R&D investment from the income statement. (Image: HB Insights. Data: ATRI SEC filings) Valuation Shares are trading at 32x trailing earnings, ahead of the sector median's 26.6x. The stock is also priced at 4.5x book value, again a step above the sector's 2.2x. We need to understand what we're buying in ATRI. Valuation is a combination of investment, return on investment and earnings by our estimate - what's real, and what's expected.
Analiz Makalesi • Aug 27

Atrion's (NASDAQ:ATRI) Upcoming Dividend Will Be Larger Than Last Year's

The board of Atrion Corporation ( NASDAQ:ATRI ) has announced that it will be paying its dividend of $2.15 on the 30th...
Seeking Alpha • Aug 22

Atrion raises dividend 10.3% to $2.15/share

Atrion (NASDAQ:ATRI) declares $2.15/share quarterly dividend, 10.3% increase from prior dividend of $1.95. Forward yield 1.38% Payable Sept. 30; for shareholders of record Sept. 15; ex-div Sept. 14. See ATRI Dividend Scorecard, Yield Chart, & Dividend Growth.
Analiz Makalesi • Jul 18

Some Investors May Be Worried About Atrion's (NASDAQ:ATRI) Returns On Capital

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
Analiz Makalesi • Jan 03

Atrion (NASDAQ:ATRI) Could Be Struggling To Allocate Capital

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Analiz Makalesi • Nov 18

Atrion's (NASDAQ:ATRI) Dividend Will Be Increased To US$1.95

Atrion Corporation ( NASDAQ:ATRI ) will increase its dividend on the 15th of December to US$1.95. This takes the annual...
Analiz Makalesi • Sep 03

Atrion's (NASDAQ:ATRI) Dividend Will Be Increased To US$1.95

Atrion Corporation's ( NASDAQ:ATRI ) dividend will be increasing to US$1.95 on 30th of September. This takes the annual...

Hissedar Getirileri

ATRIUS Medical EquipmentUS Pazar
7D0.1%-5.1%-0.2%
1Y-3.1%-17.5%14.8%

Getiri vs. Endüstri: ATRI geçen yıl % -17.5 oranında getiri sağlayan US Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: ATRI geçen yıl % 14.8 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ATRI's price volatile compared to industry and market?
ATRI volatility
ATRI Average Weekly Movement1.6%
Medical Equipment Industry Average Movement8.4%
Market Average Movement6.9%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

İstikrarlı Hisse Senedi Fiyatı: ATRI son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: ATRI 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 7% dan 2% a düştü.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
1944712David Battatwww.atrioncorp.com

Atrion Corporation Temel Bilgiler Özeti

Atrion'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ATRI temel i̇stati̇sti̇kler
Piyasa değeriUS$809.44m
Kazançlar(TTM)US$12.56m
Gelir(TTM)US$181.60m
64.5x
F/K Oranı
4.5x
P/S Oranı

ATRI aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ATRI gelir tablosu (TTM)
GelirUS$181.60m
Gelir MaliyetiUS$121.05m
Brüt KârUS$60.55m
Diğer GiderlerUS$47.99m
KazançlarUS$12.56m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)7.13
Brüt Marj33.34%
Net Kâr Marjı6.91%
Borç/Özkaynak Oranı0%

ATRI uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

1.9%
Mevcut Temettü Verimi
123%
Ödeme Oranı

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2024/08/21 08:07
Gün Sonu Hisse Fiyatı2024/08/21 00:00
Kazançlar2024/06/30
Yıllık Kazançlar2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Atrion Corporation 1 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Norbert KalliwodaDr. Kalliwoda Research